AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for ...

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug ...

Among 35 patients who received Datroway at a lower 4 mg/kg dose, investigators recorded a 43% ORR for the combination. The two patient groups had similar follow-up times at about 13 months ...

DATROWAY ® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative ...

AstraZeneca PLC on Monday said Datroway has been approved in the US for patients with a type of breast cancer. The C ... Subscribe now to see this Premium News article from Alliance News ...

Datroway is the first TROP-2 directed drug to be approved in Japan for the indication. It's also the second DXd antibody-drug conjugate, or ADC, approved based on the company's DXd ADC technology.

Datroway (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with ...

First approval in the EU for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 trial showing 37% reduction in the risk of disease progression or death versus chemotherapy ...

First approval in the EU for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 trial showing 37% reduction ...